1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Sanofi

Sanofi

SNYNF
SanofiUS flagOther OTC
86.61
USD
+2.64
- -
104.12BMarket Cap
Sanofi
SNYNF
(Other OTC)

Recent

price

86.61

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
26.08
26.52
27.25
23.65
24.32
26.69
26.97
28.82
28.61
30.11
29.81
31.28
32.4
33.25
35.39
38.28
39.19
Revenue per Share
4.19
4.27
3.7
2.81
3.34
3.28
3.66
6.7
3.45
2.2
9.81
4.97
6.69
4.31
4.44
6.4
6.25
Basic EPS, GAAP
6.28
5.7
4.97
4.27
4.74
4.71
4.74
4.31
2.86
4.74
4.26
6.77
6.73
5.87
4.7
5.91
8.56
Free Cash Flow per Basic Share
2.4
1.04
2.64
2.75
2.79
2.83
2.92
2.95
3.03
3.07
3.14
3.2
3.33
3.56
3.76
3.91
- -
Dividend per Share
2.01
2.03
2.01
2
2.01
2
2.01
2
2
2.01
2.02
2.02
2.01
2.02
2.02
2
- -
Book Value per Share
6.8
-4.43
-0.59
3.4
1.92
5.07
5.1
3.89
-5.68
-1.44
-0.34
-0.34
2.89
0.5
9.46
3.4
3.36
Tangible Book Value per Share
1,305
1,322
1,320
1,323
1,316
1,306
1,287
1,257
1,247
1,250
1,254
1,252
1,252
1,252
1,251
1,220
1,208
Basic Weighted Avg Shares
34,036
35,058
35,957
31,291
31,999
34,861
34,696
36,221
35,677
37,631
37,369
39,175
40,561
41,618
44,286
46,716
47,354
Sales/Revenue/Turnover
24.94
21.76
21.92
20.32
21.06
20.46
21.69
19.88
17.53
19.07
21.11
23.35
26.94
20.88
20.15
20.54
19.84
Operating Margin (%)
5,129
5,553
4,907
5,095
3,280
4,276
3,301
3,686
4,279
7,445
3,671
3,351
3,108
4,429
3,586
5,678
1,912
Depreciation Expense
5,467
5,646
4,888
3,716
4,390
4,287
4,709
8,416
4,306
2,754
12,294
6,223
8,371
5,400
5,560
7,813
7,555
Net Income, GAAP
23.17
8.37
19.2
16.19
21.46
13.52
23.35
31.13
10.92
4.4
13.12
19.98
19.21
16.27
17.98
16.89
16.31
Effective Tax Rate (%)
16.06
16.1
13.59
11.88
13.72
12.3
13.57
23.24
12.07
7.32
32.9
15.89
20.64
12.98
12.55
16.72
15.95
Profit Margin (%)
15,320
7,274
9,032
9,997
10,405
12,872
15,474
10,925
7,271
8,549
9,358
9,358
10,136
6,463
13,426
2,607
156
Working Capital
6,695
12,499
10,719
10,414
13,276
13,118
16,815
14,326
22,007
21,118
18,962
18,962
16,761
16,102
13,436
15,715
13,840
LT Debt
53,288
56,363
57,486
57,033
56,268
58,210
57,722
58,239
59,035
59,230
69,031
69,031
75,152
74,353
77,857
71,710
73,143
Total Equity
10.91
10.36
8.75
7.34
7.34
8.36
7.55
6.52
7
8.08
7.72
7.95
9.33
7.62
7.69
8.4
8.26
Return on Invested Capital (%)
48.89
41.46
29.91
23.46
27.11
25.29
26.2
43.34
20.38
11.33
46.88
25.61
34.96
26.02
28.92
37.81
38.21
Return on Capital (%)
207.91
212.9
183.24
140.17
166.04
163.31
181.29
330.56
172.14
110.09
488.34
246.26
331.59
213.78
219.94
314.72
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8,489
4,614
6,181
LT Borrowings
11,700
14,248
12,298
LT Finance Leases
1,566
1,467
1,542
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,218
1,208
1,198
Market Capitalization
97,296
101,335
98,082

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
34,042
30,952
30,164
Cash, Cash Equivalents & STI
8,906
8,467
5,544
Accounts Receivable, Net
- -
8,410
- -
Inventories
24,501
10,214
23,503
Total Current Liabilities
32,105
28,345
30,008
Payables & Accruals
23,614
9,045
23,650
ST Debt
8,489
4,614
6,181
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-7.9%
Free Cash Flow
5.82%
9.63%
22.53%
Net Income, GAAP
34.32%
-1.37%
40.52%
Sales/Revenue/Turnover
3.01%
4.58%
5.49%
Total Cash Common Dividend
2.62%
3.94%
1.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,726
11,380
12,977
7,631
44,286
2025
10,606
10,735
13,170
12,205
46,716
2026
11,244
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.91
- -
2.25
0.4
4.44
2025
1.52
- -
- -
-0.66
6.4
2026
1.34
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.76
2025
- -
- -
- -
- -
3.91
2026
- -
- -
- -
- -
- -
Similar Companies
Daiichi Sankyo Company, Limited (DSKYF)
Novartis AG (NVSEF)
Sanofi (SNY)
Sanofi (SAN.PA)
Kopran Limited (KOPRAN.NS)
Chugai Pharmaceutical Co., Ltd. (CHGCF)
Business
Sanofi S.A. (SNYNF) is a French multinational biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, and over-the-counter healthcare products worldwide. Founded in 1973 and headquartered at 46-48 Avenue de la Grande Armée in Paris's 17th arrondissement, the company operates in over 100 countries across Europe, the Americas, Africa, Asia-Pacific, and the Middle East, with key research and production hubs including Cambridge, Massachusetts; Bridgewater, New Jersey; and Lyon, France. Sanofi focuses on five core therapeutic areas—immunology and inflammation, neurology, oncology, rare diseases, and vaccines—delivering a broad portfolio that includes Dupixent (dupilumab) for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (marketed with Regeneron); Lantus and Toujeo (insulin glargine) for diabetes; Aubagio (teriflunomide) and tolebrutinib for multiple sclerosis; Sarclisa (isatumab) for multiple myeloma; Cerezyme (imiglucerase) and Nexviazyme (avalglucosidase alfa) for rare diseases such as Gaucher and Pompe disease; and leading vaccines like Fluzone for influenza, Menactra for meningococcal disease, and Dengvaxia for dengue via its Sanofi Pasteur subsidiary, the world's largest vaccine producer. Its immunology offerings also encompass treatments for rheumatoid arthritis (Kevzara with Regeneron), hemophilia (Eloctate, Alprolix), and thrombosis (Lovenox); cardiovascular products like Multaq (dronedarone) and Praluent (alirocumab with Regeneron); oncology agents including Jevtana (cabazitaxel) and Taxotere (docetaxel); and consumer health brands such as Allegra (fexofenadine) and Nasacort (triamcinolone). Sanofi maintains a robust R&D pipeline with 93 clinical-stage projects across its focus areas, including 26 in Phase 3 or under regulatory review, such as amlitelimab for atopic dermatitis and celiac disease, frexalimab for multiple sclerosis and type 1 diabetes, itepekimab for COPD, and next-generation vaccines like SP0256 for RSV in older adults. Recent developments include the completion of its acquisition of Vicebio Ltd. on December 4, 2025, adding a novel RSV/hMPV combination vaccine candidate leveraging Molecular Clamp technology to bolster its respiratory vaccine portfolio; an additional $625 million commitment to Sanofi Ventures in September 2025, expanding assets under management to over $1.4 billion for biotech and digital health investments following 2024 exits valued at $3.25 billion; the acquisition of Vigil Neuroscience for $470 million in May 2025 to advance neurology pipeline assets; a February 2025 share buyback of 2.3% from L'Oréal as part of its ongoing program; and a July 2025 extension of its tender offer for Blueprint Medicines to strengthen oncology capabilities. Through subsidiaries like Sanofi Genzyme (rare diseases and specialty care) and ongoing collaborations such as with Regeneron, Sanofi drives innovation in AI-powered biopharma solutions for immunology, oncology, and beyond.